Get the Stockscreener App
207.19
3.47%
-7.45
After Hours:
208.10
0.91
+0.44%
Natera Inc stock is traded at $207.19, with a volume of 1.38M.
It is down -3.47% in the last 24 hours and up +10.30% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$214.64
Open:
$217.62
24h Volume:
1.38M
Relative Volume:
1.14
Market Cap:
$29.37B
Revenue:
$2.31B
Net Income/Loss:
$-208.16M
P/E Ratio:
-134.84
EPS:
-1.5366
Net Cash Flow:
$76.11M
1W Performance:
-1.73%
1M Performance:
+10.30%
6M Performance:
+15.48%
1Y Performance:
+36.54%
1-Day Range:
$206.26
$219.47
1-Week Range:
$184.00
$219.47
52-Week Range:
$131.81
$256.36
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
207.19 | 30.42B | 2.31B | -208.16M | 76.11M | -1.5366 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Is It Time To Reassess Natera (NTRA) After Its Mixed Share Price Performance? - simplywall.st
Natera positioned to capture growing $20 billion MRD opportunity: analyst - MSN
NTRA Initiated Coverage On by William Blair -- Rating Outperform - GuruFocus
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst - Benzinga
Natera Inc stock (US6323071042): Is cell-free DNA testing strong enough to unlock sustained growth? - AD HOC NEWS
William Blair initiates coverage of Natera (NTRA) with outperform recommendation - MSN
William Blair initiates Natera stock with Outperform on growth outlook - Investing.com
William Blair initiates Natera stock with Outperform on growth outlook By Investing.com - Investing.com Canada
Natera: Premium-Valued Leader in MRD Positioned for Long-Term Growth and Margin Expansion - TipRanks
Lymphoma patients on Allogene therapy saw ctDNA drop 97.7% by Day 45 - Stock Titan
Moving Averages: Will Natera Inc benefit from sector rotation2026 Price Momentum & Daily Stock Trend Watchlist - baoquankhu1.vn
Natera Inc. (NTRA): Upside Potential Pulls Billionaire Stan Druckenmiller - MSN
Court orders 30% ongoing royalty for Natera in patent dispute - MSN
Aug Closing: Can Natera Inc outperform in the next rallyBull Run & AI Optimized Trade Strategies - baoquankhu1.vn
Assessing Natera (NTRA) Valuation After Patent Win Product Momentum And Upcoming Cancer Data - simplywall.st
A Look At Natera (NTRA) Valuation After Legal Win And Growing Signatera Adoption - Yahoo Finance
Natera Claims Top Trading Volume as Legal Victory Sparks $550 Million Surge Amid Price Drop - Bitget
Natera (NTRA) slides 4.9% as investors digest mixed signals: analyst caution, legal overhang, and post-court-ruling repositioning - Quiver Quantitative
NTRA Stock Price, Quote & Chart | NATERA INC (NASDAQ:NTRA) - ChartMill
Natera (NTRA) Secures 30% Royalty in Patent Dispute - GuruFocus
Court Win on MRD Patents and Royalties Might Change The Case For Investing In Natera (NTRA) - simplywall.st
Director Eric H. Rubin joins Natera (NTRA) insider roster with Form 3 filing - Stock Titan
Natera wins 30% ongoing royalty in patent case against Invitae By Investing.com - Investing.com Australia
3 Reasons NTRA Has Explosive Upside Potential - Yahoo Finance
Natera Inc (NTRA) Shares Gap Down to $201.16 on Apr 9 - GuruFocus
Natera (NTRA) Wins Increased Royalty in Delaware Court Decision - GuruFocus
Natera awarded 30% ongoing royalty in MRD patent litigation - MSN
Judge Awards 30% Ongoing Royalty to Natera for Its MRD-Related Patents - Moomoo
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle - Benzinga
Natera Says Court Orders 30% Royalties From ArcherDx, Invitae on Post-Injunction Sales - marketscreener.com
Natera wins 30% ongoing royalty in patent case against Invitae - Investing.com
Judge Awards 30% Ongoing Royalty to Natera for its MRD-Related Patents - Yahoo Finance
Natera (NASDAQ: NTRA) chair exercises options, uses shares for taxes - Stock Titan
Buy Signal: Can Natera Inc outperform in the next rallyWeekly Trend Recap & Short-Term Trading Alerts - baoquankhu1.vn
Voya Global Insights Portfolio's Natera Inc(NTRA) Holding History - GuruFocus
Natera Award Cut by $10 Million as Invitae Faces Royalty (1) - Bloomberg Law News
20 Abstracts at AACR Highlight Scale, Innovation and Clinical Impact of Natera’s Oncology Platform - BioSpace
Natera (NTRA) Gets 90-Day Catalyst Watch from Citi and Maintains Buy Rating - GuruFocus
56,665 Shares in Natera, Inc. $NTRA Purchased by Robinhood Asset Management LLC - MarketBeat
Citi Maintains Natera(NTRA.US) With Buy Rating, Maintains Target Price $300 - Moomoo
Natera, Inc. (NTRA) stock price, news, quote and history - Yahoo Finance Singapore
Judge Slashes Damages For Natera In Invitae Patent Case - Law360
Natera, Inc. (NTRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
NTRA SEC FilingsNatera Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Natera (NTRA) Valuation After New Signatera Breast Cancer Study Results - simplywall.st
Insider Sell Alert: Daniel Rabinowitz Sells 8,400 Shares of Nate - GuruFocus
Natera (NASDAQ:NTRA) Downgraded to Hold Rating by Wall Street Zen - MarketBeat
Natera SEC. sold $1.7m in NTRA stock By Investing.com - Investing.com Canada
Natera (NASDAQ:NTRA) Insider Solomon Moshkevich Sells 3,000 Shares of Stock - marketbeat.com
Natera president sells $606,899 in NTRA stock By Investing.com - Investing.com South Africa
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):